BioMarin Pharmaceutical Inc. develops and markets therapies for people with rare diseases and serious and life-threatening medical conditions. The company is headquartered in San Rafael, California.
| Revenue (TTM) | $3.41B |
| Gross Profit (TTM) | $1.74B |
| EBITDA | $645.32M |
| Operating Margin | 21.20% |
| Return on Equity | 1.18% |
| Return on Assets | 3.26% |
| Revenue/Share (TTM) | $17.69 |
| Book Value | $32.66 |
| Price-to-Book | 2.03 |
| Price-to-Sales (TTM) | 3.78 |
| EV/Revenue | 4.751 |
| EV/EBITDA | 41.97 |
| Quarterly Earnings Growth (YoY) | -81.30% |
| Quarterly Revenue Growth (YoY) | 19.90% |
| Shares Outstanding | $193.57M |
| Float | $192.39M |
| % Insiders | 0.34% |
| % Institutions | 103.79% |
Volatility is currently contracting
BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, reshaping the economics of competition.
Wells Fargo 21st Annual Healthcare Conference, September 9 at 3:00 pm EST Cantor Global Healthcare Conference 2026, September 10 at 10:20 am EST Citi's 2026 Biopharma Back to School Conference, September 10 at 1:00 pm EST Morgan Stanley 24th Annual Global Healthcare Conference, September 14 at 10:00 am EST SAN RAFAEL, Calif., Sept. 2, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming investor conferences in September.
ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.
Acquisition adds ALE1, a potential first oral therapy for hypophosphatasia to clinical pipeline SAN RAFAEL, Calif., Sept. 1, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Alesta Therapeutics.
Agreement Resolves all Pending Patent-Related Proceedings Between BioMarin and Ascendis SAN RAFAEL, Calif., Aug. 30, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has entered into binding terms with Ascendis Pharma A/S, resolving the patent and ancillary disputes pending globally, including before the U.S. International Trade Commission (ITC) concerning Ascendis's Yuviwel.
BMRN's $490M Alesta deal adds ALE1, a potential oral HPP therapy, broadening its rare bone disease portfolio and clinical pipeline.
BioMarin will acquire Alesta Therapeutics for $275 million upfront, and up to an additional $215 million based on milestones. Alesta Therapeutic's lead drug is a potential treatment for hypophosphatasia (HPP).
BioMarin to pay $275 million upfront, plus additional payments upon achievement of development and regulatory milestones Alesta to spin out all non-ALE1 assets to a new entity and Alesta employees to transfer to the spinout entity prior to close ALE1 has significant potential to help BioMarin expand into larger rare disease markets with a medicine intended to address a high unmet need for patients and offers strong strategic fit for the company SAN RAFAEL, Calif., Aug. 18, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that BioMarin has entered into a definitive agreement to acquire Alesta Therapeutics to gain Alesta's lead clinical-stage asset, ALE1.
Here is how BioMarin Pharmaceutical (BMRN) and Cardinal Health (CAH) have performed compared to their sector so far this year.
BioMarin, Invesco, Centene, HPE and Gibraltar Industries stand out as undervalued stocks with low price-to-book ratios.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BMRN and any ticker you trade — then tracks every position and per-strategy win rate.
